The Journal of
Clinical Psychiatry

Depression (MDD)

Article February 1, 1997

Antidepressants

Alan Frazer, Ph.D.

J Clin Psychiatry 1997;58(suppl 6):9-25

Article Abstract

This review covers the chemical structures, efficacy, side effects, toxicity, and mechanisms of actionof various classes of antidepressants: tricyclic antidepressants, monoamine oxidase inhibitors,and second generation antidepressants including the serotonin selective reuptake inhibitors, and noveldrugs such as mirtazapine, nefazodone, and venlafaxine.

Download Free PDF

This PDF is free for all visitors!

Save

Cite

INFORMATION FROM INDUSTRY

AUVELITY is an FDA-approved treatment for adults with MDD. Auvelity, is a rapid-acting antidepressant with a multimodal mechanism, targeting both glutamatergic and monoaminergic pathways. Learn more about how AUVELITY is thought to work and side effects. Please see Important Safety Information within this document and the full Prescribing Information.

Vol 86 • 2025 • Number 1

Read the Current Issue

Brief Report

Sex Differences in PTSD among US Military Veterans

Commentary

The Opioid Industry's Legacy: A Generation of Prescribed Suffering

Clinical and Practical Psychopharmacology

Cannabis Use in Pregnancy and ASD or ADHD in Offspring

Commentary

Evolving Care and Research Priorities in ADHD

Original Research

Treatments and Treatment Predictors in Patients With SUDs and ADHD

Systematic Review

Efficacy and Safety of Memantine for Children and Adults with ADHD

View current Issue

Related Articles

Article

Brain Zaps

December 20, 2018

Brain zaps are a poorly understood symptom of antidepressant discontinuation, which require further study for both better prevention and treatment. This article describes the characteristics of brain zaps and...

Alexander Papp , Julie A. Onton

Article

ECT in Obsessive-Compulsive-Related Disorders

October 18, 2018

Obsessive-compulsive-related disorders include conditions such as body dysmorphic disorder and skin-picking disorder, as well as tic disorders and self-injurious behaviors. Could electroconvulsive therapy be an effective treatment option? Read...

Samara dos Santos-Ribeiro , Juliana B. de Salles Andrade , Julliana N. Quintas , et al

Article

Glabellar Botulinum for Depression

October 4, 2018

Glabellar injection of botulinum toxin A (BTA) provides a novel and interesting strategy to address shortcomings in the treatment of depression. This study examines the primary clinical trials conducted...

Toren P. Stearns , Mujeeb U. Shad , Gabriela C. Guzman